Revision History

1 revisions for "China's Ivonescimab Shows 34% Survival Benefit in Lung Cancer — But Can a Drug That Failed in the West Succeed Globally?"

Anonymous13 days ago

Akeso's ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, reduced the risk of death by 34% in the Chinese HARMONi-6 trial for advanced squamous lung cancer — but a prior global trial missed its overall survival endpoint in Western patients, raising questions about generalizability. With an FDA decision on a separate indication expected by November 2026 and Chinese approval already secured, the drug's fate may hinge on whether regulators accept China-only data as proof of broad efficacy.